Compare Infosys Limited (INFY) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Infosys Limited vs Tilray Brands Inc — how do they compare? Infosys Limited trades at $10.73 (market cap $41.74B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: Infosys Limited is far larger — about 78.7× Tilray Brands Inc's market cap, and Infosys Limited pays a 4.89% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Infosys Limited for 27 Days and Tilray Brands Inc for 31 Days on average.
| INFY | TLRY | |
|---|---|---|
Market Cap | $41.74B | $530.54M |
Volume | 31,354,285 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $20.22 | $17.20 |
52-Week Low | $10.49 | $3.54 |
Typical Hold Time | 27 Days | 31 Days |
Enterprise Value | $39.48B | $684.46M |
Dividend Yield | 4.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INFY trades at $10.70, up 1.42% today, with a bearish technical signal from moving averages. The company reported revenue of $19.28B in 2025, with a net income margin of 16.37%. Recent news highlights strategic AI collaborations, including with Columbia University and ABN Amro. Analyst consensus is a 'Hold' with a $11.48 price target, indicating modest upside potential from current levels.
The outlook is mixed: strong profitability and recent earnings beats support the stock, but a projected negative net cash flow in 2026 and bearish technical indicators pose risks. Investor sentiment is cautious amid weak Western IT spending concerns, though institutional holdings show confidence. Key risks include competitive pressures and macroeconomic headwinds affecting IT services demand.
Tilray Brands (TLRY) trades at $3.59, down 3.36% on the day and near 52-week lows, with bearish technical indicators dominating. The company reported $821 million in revenue for 2025 but posted a massive $2.19 billion net loss due to impairment charges. Recent earnings have consistently missed expectations, though analyst consensus remains cautiously optimistic with a $65.01 price target. The stock faces significant headwinds from ongoing profitability challenges and cannabis industry volatility.
TLRY presents a high-risk opportunity with potential upside if management can achieve profitability and capitalize on cannabis reform catalysts. However, persistent losses, negative cash flow, and competitive pressures create substantial downside risk. Investors should weigh the speculative nature against potential regulatory catalysts in the coming months.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
